Kiniksa Pharmaceuticals International Plc.'s common stock is $21K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Kiniksa Pharmaceuticals International Plc. (KNSA) currently reports a common stock of $21K as of June 2026. That compares with $21K in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Kiniksa Pharmaceuticals International Plc.'s common stock history and peer comparisons.
Kiniksa Pharmaceuticals International Plc.'s common stock was unchanged from $21K to $21K — essentially flat versus a year earlier (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Kiniksa Pharmaceuticals International Plc. reported $21K in common stock as of June 2026. That compares with $21K in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $21K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Kiniksa Pharmaceuticals International Plc., and consider following KNSA for alerts when major investors trade the stock.
Kiniksa Pharmaceuticals International Plc. is classified in the Healthcare sector. On common stock, it currently shows $21K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KNSA with unrelated industries.